13F Portfolios

Duquesne Family Office LLC: NEWAMSTERDAM PHARMA COMPANY (NAMS): Quarterly 13F Position History

As of Q1 2026, Duquesne Family Office LLC reported 3,070,146 shares of NEWAMSTERDAM PHARMA COMPANY (NAMS), worth $98.3M and representing 3.3% of its 13F equity book. The position first appeared in Q3 2024 and has been disclosed across 7 13F-HR filings in Pactolio's tracked window.

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 7 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q1 2026 3,070,146 0 $98.3M 3.3% $32.0
Q4 2025 3,070,146 +1,146,446 +59.6% $107.7M 2.6% $35.1
Q3 2025 1,923,700 +1,091,525 +131.2% $54.7M 1.4% $28.4
Q2 2025 832,175 +31,815 +4.0% $15.1M 0.4% $18.1
Q1 2025 800,360 +512,825 +178.4% $16.4M 0.5% $20.5
Q4 2024 287,535 0 $7.4M 0.2% $25.7
Q3 2024 287,535 $4.8M 0.2% $16.6

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.

When did Duquesne Family Office LLC first disclose a NAMS position in 13F-HR filings?

Duquesne Family Office LLC first reported NEWAMSTERDAM PHARMA COMPANY (NAMS) on its 13F-HR filing for the period ending 2024-09-30 (Q3 2024). The position has appeared on 7 reported quarters within Pactolio's tracked window.

What was Duquesne Family Office LLC's most recent quarter-over-quarter share-count change in NAMS?

Duquesne Family Office LLC held the same 3,070,146 shares of NAMS between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.

Does the implied price-per-share represent Duquesne Family Office LLC's cost basis in NAMS?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.